GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bruker BRKR · USD

Health Care · US listing · 🇺🇸 United States

Compare

66.54

+8.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.44bn

FY2016FY2025

Net income

−$8.6m

FY2016FY2025

Free cash flow

$13.9m

FY2016FY2025

Shareholders' equity

$2.46bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$3.44bn$3.37bn$2.96bn$2.53bn$2.42bn$1.99bn$2.07bn$1.90bn$1.77bn$1.61bn
Gross profit$1.58bn$1.65bn$1.51bn$1.31bn$1.21bn$939.8m$995.3m$900.0m$813.0m$742.5m
Research and development$395.2m$376.5m$294.8m$235.9m$220.8m$198.0m$187.7m$173.4m$162.7m$149.0m
Operating income$236.0m$253.1m$443.3m$432.7m$413.3m$248.3m$300.9m$262.4m$214.7m$194.7m
Net income−$8.6m$113.1m$427.2m$296.6m$277.1m$157.8m$197.2m$179.7m$78.6m$153.6m
Diluted earnings per share-0.060.742.932.011.821.031.271.140.500.96

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$6.24bn$5.81bn$4.25bn$3.61bn$3.65bn$3.05bn$2.77bn$2.13bn$1.95bn$1.81bn
Cash and short-term investments$298.8m$183.4m$488.3m$645.5m$1.17bn$731.8m$684.9m$322.4m$439.2m$500.3m
Total liabilities$3.73bn$3.99bn$2.84bn$2.48bn$2.57bn$2.07bn$1.83bn$1.22bn$1.22bn$1.12bn
Debt$1.87bn$2.09bn$1.28bn$1.22bn$1.33bn$844.5m$813.3m$341.1m$415.6m$411.7m
Shareholders' equity$2.46bn$1.78bn$1.38bn$1.11bn$1.07bn$961.2m$906.8m$905.1m$733.5m$693.1m
Shares outstanding153m152m146m148m153m154m155m157m156m161m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$134.1m$251.3m$350.1m$262.0m$282.4m$333.2m$213.4m$239.7m$154.4m$130.8m
Capital spending−$120.2m−$115.3m−$106.9m−$119.0m−$92.0m−$98.2m−$73.0m−$49.2m−$43.7m−$37.1m
Free cash flow$13.9m$136.0m$243.2m$143.0m$190.4m$235.0m$140.4m$190.5m$110.7m$93.7m
Dividends paid−$22.8m−$30.2m−$29.4m−$29.8m−$24.2m−$24.6m−$25.0m−$25.1m−$25.4m−$25.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$838.5m$823.4m$977.2m$860.5m$797.4m$801.4m$979.6m$864.4m
Gross profit$416.0m$389.3m$449.2m$379.4m$357.9m$391.2m$493.3m$418.8m
Operating income−$65.3m$45.0m$79.4m$35.0m$11.9m$31.8m$72.1m$68.1m
Net income−$52.0m$14.4m$26.0m−$59.6m$7.6m$17.4m$13.7m$40.9m
Diluted earnings per share-0.340.090.17-0.390.050.110.090.27
Cash from operations−$77.0m$71.0m$229.0m−$33.0m−$127.0m$65.0m$190.0m$38.0m
Capital spending−$28.0m−$24.0m−$22.0m−$20.0m−$21.0m−$26.0m−$36.0m−$32.0m
Free cash flow−$105.0m$47.0m$207.0m−$53.0m−$148.0m$39.0m$154.0m$6.0m
Total assets$6.05bn$6.13bn$6.24bn$6.43bn$6.34bn$5.93bn$5.81bn$6.11bn
Cash and short-term investments$184.9m$133.4m$298.8m$293.1m$92.0m$184.2m$183.4m$148.1m
Debt$1.92bn$1.67bn$1.90bn$2.01bn$2.44bn$2.11bn$2.13bn$2.30bn
Shareholders' equity$2.40bn$2.45bn$2.46bn$2.43bn$1.80bn$1.82bn$1.78bn$1.81bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin45.9%49.0%51.0%51.6%50.0%47.3%
Operating margin2.4%7.6%18.9%17.0%16.9%12.1%
Net margin-0.3%3.4%14.4%11.7%11.5%7.9%
Return on equity-0.4%6.3%31.0%26.6%25.9%16.4%
Return on assets-0.1%1.9%10.1%8.2%7.6%5.2%
Free cash flow yield3.0%4.3%5.6%4.6%4.4%5.0%
Revenue growth2.1%13.6%17.1%4.7%21.7%-4.1%
Earnings growth-107.6%-73.5%44.0%7.0%75.6%-20.0%
Current ratio1.73x1.60x1.80x2.31x2.63x2.43x
Debt to equity0.78x1.19x0.95x1.11x1.26x0.90x
Equity ratio39.4%30.7%32.4%30.8%29.3%31.5%
Interest coverage1.36x5.32x34.18x26.71x28.52x16.68x
R&D as a share of sales11.5%11.2%9.9%9.3%9.1%10.0%
Buybacks as a share of market value-0.3%-4.1%1.3%3.0%0.8%1.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.7%11.6%7.8%
Operating income-18.3%-1.0%4.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin47.4%49.2%49.1%48.1%
Operating margin7.2%11.1%12.1%12.3%
Net margin1.5%6.7%7.6%7.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-835.478.825.134.146.252.840.226.168.022.2
Price to sales2.12.63.64.05.34.23.82.53.02.1

Market value over time

30 Nov 2016 to 13 Oct 2026, in USD

$3.66bn$8.55bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-19%-26%17%-18%42%6%82%-17%60%-9%

Dividends and splits

Per share, in the currency the company pays

Paid for 10 years. Last went ex-dividend on 21 Sept 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.150.200.200.200.200.160.160.16

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.